GlassScriptPhysician profile
Debra A Becker
NPI 1497791537
$10,035.32
in general payments reported to CMS, 2019-2025
40 companies · $1,346 in 2025
The $1,346 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,560 · 2020: $1,123 · 2021: $1,195 · 2022: $1,773 · 2023: $1,678 · 2024: $1,360 · 2025: $1,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,384.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,546.86 | 2019-2025 | |
| Amgen INC. | $1,305.78 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $848.69 | 2019-2024 | Xarelto |
| Pfizer INC. | $752.84 | 2019-2025 | |
| Abbott Laboratories | $653.76 | 2019-2025 | Jot Dx, Aveir, Amplatzer Amulet |
| E.R. Squibb & Sons, L.L.C. | $512.08 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $508.83 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $463.41 | 2019-2024 | |
| Philips North America LLC | $355.86 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided, (5091) Amb Mon & Diag Und, (Cm9) Amb Mon & Diag Und |
| Astrazeneca Pharmaceuticals LP | $319.57 | 2019-2025 | Farxiga, Wainua |
| Amarin Pharma, INC. | $308.09 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $281.20 | 2021-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $250.41 | 2020-2023 | Lifevest |
| Boston Scientific Corporation | $248.92 | 2019-2025 | Watchman Flx |
| Alnylam Pharmaceuticals INC. | $230.62 | 2022-2025 | Onpattro |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.